12399456https://www.upal.com.my/zh/feeds/jobFeedKwongwahArray ( [0] => HTTP/1.1 200 OK [1] => Date: Sun, 22 Feb 2026 06:54:34 GMT [2] => Content-Type: text/xml; charset=utf-8 [3] => Connection: close [4] => Cache-Control: no-cache, private [5] => Cache-Control: no-cache, no-store, must-revalidate [6] => Set-Cookie: UpalLiveSession=eyJpdiI6InBJcDM1dzJmXC91cHBFdlcwZHNQNjNBPT0iLCJ2YWx1ZSI6ImVmTTJlaHloTFo3WUhwUUE1NjdzRUc2ODNrTjM2MlBtaThReGVWZkliVW9FdHVMS01vYXllZEMwNDhJaEtDbUY3clBoQ0p2R0d3MXBSTmVNTFNPXC9mdz09IiwibWFjIjoiN2Q2ZDZmZDg5MTQ1NzM0NGJiMjk4YjgzZmE3NTNhZDM3YzFkNzRkMmJlNjY1N2NjZjkxOGY3MmFlZDIwMGVkMSJ9; expires=Wed, 21-Feb-2029 06:54:34 GMT; Max-Age=94608000; path=/; HttpOnly [7] => x-frame-options: SAMEORIGIN [8] => x-content-type-options: nosniff [9] => x-xss-protection: 1; mode=block [10] => referrer-policy: strict-origin-when-cross-origin [11] => permissions-policy: geolocation=(), microphone=(), camera=() [12] => content-security-policy: default-src * 'unsafe-inline' 'unsafe-eval' data: blob:; script-src * 'unsafe-inline' 'unsafe-eval' data: blob:; style-src * 'unsafe-inline' data:; img-src * data: blob:; font-src * data:; connect-src *; frame-src *; object-src *; media-src *; child-src *; [13] => Server: cloudflare [14] => x-robots-tag: noindex, nofollow, nosnippet, noarchive [15] => strict-transport-security: max-age=31536000; includeSubDomains; preload [16] => expires: Mon, 23 Feb 2026 06:54:34 GMT [17] => vary: Accept-Encoding [18] => Report-To: {"group":"cf-nel","max_age":604800,"endpoints":[{"url":"https://a.nel.cloudflare.com/report/v4?s=8xHjBz4oIYZ6jK7RTgUeB4saleGHmrC0pY9Vcy5oAkSEh8gAsKJj0Sd3mkPXXgJXD%2FE3QdcakFVmzW5okZ5Q6UnvCrPHKxH0Luy3wh%2FAtg%3D%3D"}]} [19] => cf-cache-status: DYNAMIC [20] => Nel: {"report_to":"cf-nel","success_fraction":0.0,"max_age":604800} [21] => Speculation-Rules: "/cdn-cgi/speculation" [22] => Server-Timing: cfCacheStatus;desc="DYNAMIC" [23] => Server-Timing: cfEdge;dur=18,cfOrigin;dur=231 [24] => CF-RAY: 9d1c92a78a77fde8-SIN [25] => alt-svc: h3=":443"; ma=86400 ) 789

 

 

美国食品及药物管理局（FDA）宣布批准了第一款用于治疗小儿脊髓性肌萎缩症（SMA）的基因疗法Zolgensma。Zolgensma由AveXis公司研发，2018年4月，诺华收购了AveXis，并获得了该基因疗法。SMA是一种罕见的遗传性疾病，患儿用于编码运动神经元生存蛋白（SMN）的基因突变，因而出现进行性肌肉无力、瘫痪等症状，严重时，在2岁时死亡。

Zolgensma通过单次静脉注射，向患儿SMN基因的功能性拷贝，从而通过持续的SMN蛋白表达来阻止疾病进展。Zolgensma也成为FDA批准的首款用于治疗SMA的基因疗法。诺华将Zolgensma的售价定为212万美元，堪称‘史上最贵药物’。

---

// // // //